Body habitus changes related to lipodystrophy

Clinical Infectious Diseases

Volumn 36, Issue SUPPL. 2, 2003, Pages

  Sattler, Fred ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANDROGEN; ANTIRETROVIRUS AGENT; DIDANOSINE; HUMAN GROWTH HORMONE; INDINAVIR; LAMIVUDINE; METFORMIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TESTOSTERONE; TROGLITAZONE; ZIDOVUDINE;

ANTHROPOMETRIC PARAMETERS; ATHEROSCLEROSIS; BODY FAT; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFECT; FAT BODY; HIGH FIBER DIET; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSULIN RESISTANCE; KINESIOTHERAPY; LIPID BLOOD LEVEL; LIPID STORAGE; LIPIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LOW FAT DIET; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SUBCUTANEOUS FAT; TREATMENT OUTCOME;

ANDROGENS; EXERCISE; GROWTH HORMONE; HIV INFECTIONS; HUMANS; INCIDENCE; LIPODYSTROPHY; METFORMIN; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 0037385537     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367563     Document Type: Review

References (65)

1. Wanke CA. Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. AIDS 1999; 13:1287-93.
2. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-505.
3. Reaven GM. Syndrome X: 6 years later. J Intern Med Suppl 1994; 736:13-22.
4. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25:312-21.
5. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
6. Estrada V, Serrano-Rios M, Martinez Larrad MT, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:32-40.
7. Deedwania PC. The deadly quartet revisited. Am J Med 1998; 105:1S-3S.
8. Goujard C, Boufassa F, Deveau C, Laskri D, Meyer L. Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection. AIDS 2001; 15:282-4.
9. Martinez E, Mocroft A, Garcia-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-8.
10. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-9.
11. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000; 31:1482-7.
12. Galli M, Veglia F, Angarano G, et al. Risk of developing metabolic and morphological alterations under antiretroviral therapy according to the drug combinations [abstract P61]. Antivir Ther 2000; 5(Suppl 5):59-60.
13. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-98.
14. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-9.
15. Falutz J, Murrahainen N, Workman C, et al. Gender is associated with increased body size but not fat depletion in patients with HIV-associated adipose redistribution (HARS) [abstract WePeB4273]. In: Program and abstracts of the 13th International AIDS Conference (Durban, South Africa). 2000; 95.
16. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84:1932-7.
17. Lichtenstein K, Delaney K, Ward D, Palella F. Clinical factors associated with incidence and prevalence of fat atrophy and accumulation [abstract P64]. Antivir Ther 2000; 5(Suppl 5):61-2.
18. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465-71.
19. McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74:679-86.
20. Galli M, Cozzi-Lipri A, Ridolfo A, et al. Risk of developing adipose tisue alterations after starting antiretroviral therapy in naive patients [abstract P60]. Antivir Ther 2000; 5(Suppl 5):59.
21. Viciana P, Alarcon A, Martin D, et al. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz [abstract 48]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2000; 84.
22. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6:9-20.
23. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
24. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-32.
25. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-16.
26. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
27. Shikuma CM, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-9.
28. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002; 30:271-7.
29. Viard J, Rakotoambinina B. Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a protease inhibitor [abstract 026]. In: Program and abstracts of the 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV (San Diego). 1999; 32-33.
30. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-67.
31. Bernasconi E, Boubaker K, Sudre P, et al. Metabolic side effects of antiretrovirai therapy in the Swiss Cohort Study [abstract ThOrB703]. In: Programs and abstracts of the 13th International AIDS Conference. 2000; 296.
32. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14:37-49.
33. Saint-Marc T, Partisani M, Poizot-Martin I, Touraine J. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy [abstract 52]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). 2000; 85.
34. Joly V, Flandre P, Meiffredy V, et al. Assessment of lipodystrophy in patients previously exposed to AZT, DDI, or DDC, but naive for d4T and protease inhibitors, and randomized between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR Trial) [abstract 539]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). 2001; 205.
35. Schrooten W, de Mey I, Koitz G, Goebel F, Dreezen C, Colebunders R. Lipodystrophy and antiretroviral treatment [abstract WePeB4268]. In: Program and abstracts of the 13th International AIDS conference (Durban). 2000; 94.
36. Domingo P, Francia E, Torres O, et al. Differential effects of zidovudine and stavudine on fat distribution and its associated metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy [abstract ThOrB705]. In: Programs and abstracts of the 13th International AIDS Conference (Durban). 2000; 296.
37. Bogner J, Michl G, Neufhofer W, Vielhauer V, Walli R, Goebel F. No difference in lipodystrophy incidence in stavudine versus zidovudine nucleoside backbone: blinded evaluation in a cohort on first line HAART [abstract P54]. Antivir Ther 2000; 5(Suppl 5):55.
38. Amard P, Saint-Marc T, Katz P. The effects of polylactic acid as therapy for lipodystrophy of the face [abstract P94]. Antivir Ther 2000; 5(Suppl 5):76.
39. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358-65.
40. Jaque S, Schroeder E, Azen S, et al. Regional body composition changes during anabolic therapy. Clin Exerc Physiol 2002; 4:50-9.
41. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-7.
42. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98:398-404.
43. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100:3149-53.
44. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-74.
45. Carr A, Workman C, Smith DE, et al., the Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215.
46. McComsey G, Lonegran T, Fisher R, et al. Improvements in lipoatrophy are observed after 24 weeks when stavudine is replaced by either abacavir or zidovudine [abstract 701-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). 2002; 309.
47. John M, James I, McKinnon E, et al. A randomized, controlled, open-label study of revision of antiretroviral regimens containing stavudine and/or a protease inhibitor to zidovudine/lamivudine/abacavir to prevent or reverse lipoatrophy: 48 week data [abstract 700-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). 2002; 308.
48. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996; 125:873-82.
49. Paton NI, Newton PJ, Sharpstone DR, et al. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients. AIDS 1999; 13:1195-202.
50. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13:2099-103.
51. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82:727-34.
52. Engelson E, Glesby M, Sheikan J, Mendez D, Wang J, Kotler D. Body composition changes during and after growth hormone therapy for lipodystrophy with truncal obesity [abstract ThPpB1437]. In: Program and abstracts of the 13th International AIDS Conference (Durban). 2000; 302.
53. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001; 86:3480-7.
54. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002; 87:942.
55. Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80:239-43.
56. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13:1000-2.
57. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284:472-7.
58. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000; 133:92-103.
59. Schwartz RS, Shuman WP, Larson V, et al. The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism 1991; 40:545-51.
60. Krotkiewski M, Bjorntorp P. Muscle tissue in obesity with different distribution of adipose tissue. Effects of physical training. Int J Obes 1986; 10:331-41.
61. Lamarche B, Despres JP, Pouliot MC, et al. Is body fat loss a determinant factor in the improvement of carbohydrate and lipid metabolism following aerobic exercise training in obese women? Metabolism 1992; 41:1249-56.
62. Roubenoff R, Schmitz H, Bairos L, et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 2002; 34:390-3.
63. Roubenoff R, McDermott A, Weiss L, et al. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 1999; 13:231-9.
64. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 1999; 13:1373-5.
65. Hadigan C, Jeste S, Anderson EJ, Tsay R, Cyr H, Grinspoon S. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin Infect Dis 2001; 33:710-7.